Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2022-03-02 Proxy Solicitation & In…
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Eyegene Inc. It details the meeting date, location, agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits), and voting procedures (including electronic voting). This document is a standard proxy statement/notice of meeting sent to shareholders to solicit their participation and votes. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category.
2022-03-02 Korean
투자판단관련주요경영사항(대상포진 백신 EG-HZ 국내 기술이전 계약 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene) announcing a technology transfer agreement (licensing deal) for a shingles vaccine. It details the contract parties, financial terms (upfront payments and milestones), and contract duration. This type of disclosure regarding significant business agreements, specifically technology licensing or M&A-related partnerships, falls under the 'Regulatory Filings' (RNS) category as it is a material event announcement that does not fit into specific categories like M&A (which usually implies corporate mergers/acquisitions) or capital changes.
2022-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene) disclosing a significant change in financial structure (revenue or profit/loss fluctuation of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for public companies to report preliminary financial results or significant changes before the final audit report is finalized. It provides key financial highlights and the reasons for the change, fitting the definition of an Earnings Release (ER) as it serves as the initial announcement of financial performance. FY 2021
2022-02-23 Korean
투자판단관련주요경영사항(아이진 mRNA 기반 코로나-19 예방백신 (EG-COVID) 호주 부스터 임상 제 1/2a상 시험 계획 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the approval of a Phase 1/2a clinical trial for a COVID-19 vaccine (EG-COVID) in Australia. Since this is a specific regulatory disclosure of a material event (clinical trial approval) rather than a financial report, dividend notice, or management change, it falls under the 'Regulatory Filings' category as the most appropriate classification for miscellaneous material disclosures.
2022-02-21 Korean
기타경영사항(자율공시)([국책과제 선정] 코로나19 치료제.백신 개발 - 코로나 19 백신 임상 지원)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure ('자율공시') from the company Eutilex (아이진) regarding the selection of a government-funded project for COVID-19 vaccine clinical trial support. It details the project name, duration, funding scale, and strategic objectives. Since this is a specific regulatory announcement regarding business operations and project funding that does not fit into financial reporting, dividend notices, or management changes, it falls under the 'Regulatory Filings' category as a general corporate announcement.
2022-02-08 Korean
투자판단관련주요경영사항(mRNA 기반 코로나-19 예방백신 (EG-COVID) 부스터 임상 제 1/2a상 시험 계획 남아프리카공화국 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the company's application for a Phase 1/2a clinical trial for a COVID-19 vaccine in South Africa. Since this is a formal regulatory disclosure of a material business event (clinical trial application) that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-02-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.